Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1(+) Myeloma Cells and Release Type-1 Cytokines

Background: Multiple myeloma (MM) remains incurable despite significant advances in chemotherapy, targeted therapies, and immunotherapy. Bispecific antibody (BiAb)-armed activated T cells (BATs) have been developed for targeting and treatment of solid and hematologic malignancies. BATs are serial ki...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Oncol
Hauptverfasser: Lum, Lawrence G., Thakur, Archana, Elhakiem, Abdalla, Alameer, Lena, Dinning, Emily, Huang, Manley
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2020
Schlagworte:
Oncology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7214537/
https://ncbi.nlm.nih.gov/pubmed/32432032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00544
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge